Why the study?
Does inhibition of Eag and HERG potassium channels reduce tumour progression and cell proliferation in cancer?
Does inhibition of Eag and HERG potassium channels reduce tumour progression and cell proliferation in cancer?
Eag and HERG potassium channels are implicated in cancer cell proliferation and their inhibition may serve as a novel therapeutic strategy for tumour progression.
Hypothesis-generating for potassium channel modulators in oncology; should not yet change clinical practice.
Voltage gated potassium channels have been extensively studied in relation to cancer. In this review, we will focus on the role of two potassium channels, Ether à-go-go (Eag), Human ether à-go-go related gene (HERG), in cancer and their potential therapeutic utility in the treatment of cancer. Eag and HERG are expressed in cancers of various organs and have been implicated in cell cycle progression and proliferation of cancer cells. Inhibition of these channels has been shown to reduce proliferation both in vitro and vivo studies identifying potassium channel modulators as putative inhibitors of tumour progression. Eag channels in view of their restricted expression in normal tissue may emerge as novel tumour biomarkers.
No takes yet. Share an insight, caveat, or question.
Asher et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: